Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia

Pharmaceutical Research

Volumn 29, Issue 12, 2012, Pages 3335-3346

  Ong, Hui Xin ^a   Traini, Daniela ^a   Cipolla, David ^b   Gonda, Igor ^b   Bebawy, Mary ^c   Agus, Helen ^a   Young, Paul M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ARADIGM CORPORATION   (United States)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Calu 3; Ciprofloxacin; Liposomes; Nebulisation; Twin stage impinger

Indexed keywords

CIPROFLOXACIN; LIPOSOME; NANOPARTICLE;

AEROSOL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; DRUG TRANSPORT; DRUG UPTAKE; IN VITRO STUDY; LASER DIFFRACTION; LIPOSOMAL DELIVERY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; CELL LINE; CIPROFLOXACIN; HUMANS; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

EID: 84872118822     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0827-0     Document Type: Article

References (40)

1. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr. 2007;19:83.
2. Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383-93. (Pubitemid 34754612)
3. Geller DE. Aerosol antibiotics in cystic fibrosis. Respiratory Care. 2009;54:658-70.
4. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnel A, Sahn SA, Smith LJ, Steward JO. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481-5. (Pubitemid 30647187)
5. *. Chest. 2005;127:1420.
6. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Delivery. 2008;21:71-6.
7. Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, Doroszkiewicz W, Kozubek A. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gramnegative clinical bacterial strains. Lett Drug Des Discovery. 2007;4:297-304. (Pubitemid 46708895)
8. Drulis-Kawaand Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm. 2010;387:187-98.
9. Bakker-Woudenberg IAJM, ten Kate MT, Guo L, Working P, Mouton JW. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother. 2001;45:1487.
10. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Controlled Release. 2003;92:265-73. (Pubitemid 38366150)
11. Yim D, Blanchard JD, Mudumba S, Eastman S, Manda K, Redelmeier T, Farr SJ. The development of inhaled liposomeencapsulated ciprofloxcin to treat cystic fibrosis. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors. Respiratory drug delivery X, vol. 2. River Grove: Davis Healthcare Int'l Publishing LCC; 2006. p. 425-8.
12. Bruinenberg P, Blanchard JD, Cipolla DC, Dayton F, Mudumba S, Gonda I. Inhaled liposomal ciprofloxain: once a day management of respiratory infections. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors. Respiratory drug delivery, vol. 1. River Grove: Davis Healthcare International Publishing; 2010.
13. Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer U, Hanes J, Lehr CM. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med. 2002;15:131-9. (Pubitemid 34827526)
14. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med. 2005;18:137-82. (Pubitemid 40911357)
15. Ong HX, Traini D, Bebawy M, Young PM. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm Res. 2011;28:2327-38.
16. Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res. 2006;23:1482-90. (Pubitemid 43993811)
17. Cavet ME, West M, Simmons NL. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells. Antimicrob Agents Chemother. 1997;41:2693.
18. Grainger C, Greenwell L, Martin G, Forbes B. The permeability of large molecular weight solutes following particle delivery to airinterfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm. 2009;71:318-24.
19. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time-and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm. 2010;36:1207-14.
20. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, Bakowsky U. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther. 2005;18:165.
21. Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, Logan P, Hope MJ. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother. 1998;42:45.
22. Cipolla DC, Dayton F, Fulzale S, Gabatan E, Mudumba S, Yim D, Wu H, Zwilinski R. Inhaled liposomal ciprofloxacin: In vitro properties and aerosol performance. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery, vol. 2. River Grove: Davis Healthcare Int'l Publishing; 2010. p. 409-14.
23. Vecellio None L, Grimbert D, Becquemin M, Boissinot E, Le Pape A, LemariÈ E, Diot P. Validation of laser diffraction method as a substitute for cascade impaction in the European Project for a Nebulizer Standard. J Aerosol Med. 2001;14:107-14. (Pubitemid 32428975)
24. Dumouchel C, Yongyingsakthavorn P, Cousin J. Light multiple scattering correction of laser-diffraction spray drop-size distribution measurements. Int J Multiphase Flow. 2009;35:277-87.
25. Pharmacopoeia British. Consistency of Formulated Preparations, vol. 5. London: HMSO; 2011.
26. Chan JGY, Kwok PCL, Young PM, Chan H-K, Traini D. Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. J Pharm Sci. 2011;100:2693-702.
27. National Committee for Clinical Laboratory Standards. Tests to assess bactericidal activity: approved standard M2-A6. Wayne: NCCLS; 1996.
28. Meers P, Neville M, Malinin V, Scotto A, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins W. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61:859.
29. Cipolla DC, Redelmeier T, Eastman S, Bruinenberg P, Gonda I. Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery Europe 2011. Rover Grove: Davis Healthcare Int'l Publishing; 2010. p. 41-54.
30. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1-9. (Pubitemid 351467152)
31. Zieglerand J, Wachtel H. Comparison of cascade impaction and laser diffraction for particle size distribution measurements. J Aerosol Med. 2005;18:311-24. (Pubitemid 41395733)
32. Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm. 1995;115:69-78.
33. Bruinenberg P, Serisier D, Cipolla DC, Blanchard JD. Safety, tolerability, pharmacokinetics and antimicrobial activity of inhaled liposomal ciprofloxacin formulations in humans. Pediatr Pulm. 2010;45:354, 77.
34. Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2016-22. (Pubitemid 43807520)
35. Furneri PM, Fresta M, Puglisi G, Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000;44:2458.
36. Jia Y, Joly H, Omri A. Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa. J Liposome Res. 2010;20:134-46.
37. Hancock REW. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998;27:S93.
38. Woodruff W, Parr Jr T, Hancock R, Hanne L, Nicas T, Iglewski B. Expression in Escherichia coli and function of Pseudomonas aeruginosa outer membrane porin protein F. J Bacteriol. 1986;167:473.
39. Lohnerand K, Prenner EJ. Differential scanning calorimetry and X-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1999;1462:141-56.
40. Hopeand MJ, Wong KF. Liposomal formulation of ciprofloxacin. In: Shek PN, editor. Liposomes in biomedical applications. Germany: Harwood Academic Publishers; 1995. p. 121-34.